렉키로나주
Sign in to saveRegdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.tradename
- Regkirona
- Drug.licence_EU
- yes
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BD06
- Drug.legal_AU
- S4
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 2444308-95-4
- Drug.DrugBank
- DB16405
- Drug.UNII
- I0BGE6P6I6
- Drug.KEGG
- D12241
- Drug.synonyms
- CT-P59
via Wikipedia infobox